|
US723561A
(en)
*
|
1902-03-28 |
1903-03-24 |
Helen M Van Etten |
Artificial fuel.
|
|
US4166452A
(en)
|
1976-05-03 |
1979-09-04 |
Generales Constantine D J Jr |
Apparatus for testing human responses to stimuli
|
|
US4256108A
(en)
|
1977-04-07 |
1981-03-17 |
Alza Corporation |
Microporous-semipermeable laminated osmotic system
|
|
US4265874A
(en)
*
|
1980-04-25 |
1981-05-05 |
Alza Corporation |
Method of delivering drug with aid of effervescent activity generated in environment of use
|
|
US4738851A
(en)
|
1985-09-27 |
1988-04-19 |
University Of Iowa Research Foundation, Inc. |
Controlled release ophthalmic gel formulation
|
|
US4882150A
(en)
|
1988-06-03 |
1989-11-21 |
Kaufman Herbert E |
Drug delivery system
|
|
US5521222A
(en)
|
1989-09-28 |
1996-05-28 |
Alcon Laboratories, Inc. |
Topical ophthalmic pharmaceutical vehicles
|
|
US5077033A
(en)
|
1990-08-07 |
1991-12-31 |
Mediventures Inc. |
Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
|
|
DK0495421T3
(da)
|
1991-01-15 |
1996-12-09 |
Alcon Lab Inc |
Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
|
|
US5728536A
(en)
*
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
|
NZ274978A
(en)
*
|
1993-10-12 |
1998-04-27 |
Du Pont Merck Pharma |
1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof
|
|
IL114193A
(en)
|
1994-06-20 |
2000-02-29 |
Teva Pharma |
Ophthalmic pharmaceutical compositions based on sodium alginate
|
|
ES2094688B1
(es)
|
1994-08-08 |
1997-08-01 |
Cusi Lab |
Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
|
|
US6316635B1
(en)
*
|
1995-06-07 |
2001-11-13 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
|
GB9523675D0
(en)
*
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
IT1283911B1
(it)
|
1996-02-05 |
1998-05-07 |
Farmigea Spa |
Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
|
|
US6696448B2
(en)
*
|
1996-06-05 |
2004-02-24 |
Sugen, Inc. |
3-(piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
|
|
US6784194B2
(en)
*
|
1996-12-06 |
2004-08-31 |
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) |
Therapeutic use of a thienylcyclohexylamine derivative
|
|
US5800807A
(en)
|
1997-01-29 |
1998-09-01 |
Bausch & Lomb Incorporated |
Ophthalmic compositions including glycerin and propylene glycol
|
|
US6316429B1
(en)
*
|
1997-05-07 |
2001-11-13 |
Sugen, Inc. |
Bicyclic protein kinase inhibitors
|
|
US6486185B1
(en)
*
|
1997-05-07 |
2002-11-26 |
Sugen, Inc. |
3-heteroarylidene-2-indolinone protein kinase inhibitors
|
|
GB9718913D0
(en)
*
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
|
US6133305A
(en)
*
|
1997-09-26 |
2000-10-17 |
Sugen, Inc. |
3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
|
|
US6261547B1
(en)
|
1998-04-07 |
2001-07-17 |
Alcon Manufacturing, Ltd. |
Gelling ophthalmic compositions containing xanthan gum
|
|
US6197934B1
(en)
|
1998-05-22 |
2001-03-06 |
Collagenesis, Inc. |
Compound delivery using rapidly dissolving collagen film
|
|
GB9828511D0
(en)
*
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
|
US6841567B1
(en)
*
|
1999-02-12 |
2005-01-11 |
Cephalon, Inc. |
Cyclic substituted fused pyrrolocarbazoles and isoindolones
|
|
US6624171B1
(en)
*
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
|
US6080747A
(en)
*
|
1999-03-05 |
2000-06-27 |
Hughes Institute |
JAK-3 inhibitors for treating allergic disorders
|
|
GB9914258D0
(en)
*
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
AU4903201A
(en)
*
|
1999-11-30 |
2001-07-03 |
Parker Hughes Institute |
Inhibitors of thrombin induced platelet aggregation
|
|
US6610688B2
(en)
*
|
1999-12-21 |
2003-08-26 |
Sugen, Inc. |
4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
|
|
JP4739632B2
(ja)
*
|
2000-02-05 |
2011-08-03 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ｅｒｋのインヒビターとして有用なピラゾール組成物
|
|
JP4783532B2
(ja)
*
|
2000-02-05 |
2011-09-28 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ｅｒｋのインヒビターとして有用なピラゾール組成物
|
|
GB0004886D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
|
US6608048B2
(en)
*
|
2000-03-28 |
2003-08-19 |
Wyeth Holdings |
Tricyclic protein kinase inhibitors
|
|
GB0016877D0
(en)
*
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
|
PE20020776A1
(es)
*
|
2000-12-20 |
2002-08-22 |
Sugen Inc |
Indolinonas 4-aril sustituidas
|
|
AUPR279101A0
(en)
*
|
2001-01-30 |
2001-02-22 |
Cytopia Pty Ltd |
Protein kinase signalling
|
|
CA2450769A1
(en)
*
|
2001-06-15 |
2002-12-27 |
Vertex Pharmaceuticals Incorporated |
5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
|
|
US6939874B2
(en)
*
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
US7115617B2
(en)
*
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
US6433018B1
(en)
*
|
2001-08-31 |
2002-08-13 |
The Research Foundation Of State University Of New York |
Method for reducing hypertrophy and ischemia
|
|
JP2005506982A
(ja)
*
|
2001-09-10 |
2005-03-10 |
スージェン・インコーポレーテッド |
キナーゼ阻害剤としての３−（４，５，６，７−テトラヒドロインドール−２−イルメチリデン）−２−インドリノン誘導体
|
|
EP1453516A2
(de)
*
|
2001-10-17 |
2004-09-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
|
|
JP4460292B2
(ja)
*
|
2001-10-17 |
2010-05-12 |
ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト |
ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法
|
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US6998391B2
(en)
*
|
2002-02-07 |
2006-02-14 |
Supergen.Inc. |
Method for treating diseases associated with abnormal kinase activity
|
|
US7288547B2
(en)
*
|
2002-03-11 |
2007-10-30 |
Schering Ag |
CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents
|
|
CA2487679A1
(en)
*
|
2002-05-30 |
2003-12-11 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of jak and cdk2 protein kinases
|
|
IL166241A0
(en)
*
|
2002-07-29 |
2006-01-15 |
Rigel Pharmaceuticals Inc |
Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
|
|
JP2006502183A
(ja)
*
|
2002-09-20 |
2006-01-19 |
アルコン，インコーポレイテッド |
ドライアイ障害の処置のためのサイトカイン合成インヒビターの使用
|
|
EP1562911B1
(en)
*
|
2002-11-01 |
2010-01-06 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of jak and other protein kinases
|
|
AR042052A1
(es)
*
|
2002-11-15 |
2005-06-08 |
Vertex Pharma |
Diaminotriazoles utiles como inhibidores de proteinquinasas
|
|
ES2421139T3
(es)
*
|
2003-07-30 |
2013-08-29 |
Rigel Pharmaceuticals, Inc. |
Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
|
|
DK1663242T3
(da)
*
|
2003-08-07 |
2011-08-01 |
Rigel Pharmaceuticals Inc |
2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
|
|
DE10349423A1
(de)
*
|
2003-10-16 |
2005-06-16 |
Schering Ag |
Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
|
EP1694652A1
(en)
*
|
2003-12-19 |
2006-08-30 |
Rigel Pharmaceuticals, Inc. |
Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates
|
|
JP4812763B2
(ja)
*
|
2004-05-18 |
2011-11-09 |
ライジェル ファーマシューティカルズ， インコーポレイテッド |
シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
|
|
US20060058525A1
(en)
*
|
2004-09-01 |
2006-03-16 |
Rajinder Singh |
Synthesis of 2,4-pyrimidinediamine compounds
|
|
EP1794134A1
(de)
*
|
2004-09-29 |
2007-06-13 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 2-anilinopyrimidine als zellzyklus -kinase oder rezeptortyrosin-kinase inhibitoren, deren herstellung und verwendung als arzneimittel
|
|
ATE540035T1
(de)
*
|
2004-11-24 |
2012-01-15 |
Rigel Pharmaceuticals Inc |
Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
|
|
US7449458B2
(en)
*
|
2005-01-19 |
2008-11-11 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
WO2006133426A2
(en)
*
|
2005-06-08 |
2006-12-14 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
EP1896134A2
(en)
*
|
2005-06-13 |
2008-03-12 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions for treating degenerative bone disorders
|
|
WO2007053844A2
(en)
*
|
2005-10-31 |
2007-05-10 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for treating inflammatory disorders
|
|
US7713987B2
(en)
*
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
|
KR101411695B1
(ko)
*
|
2006-02-17 |
2014-07-03 |
리겔 파마슈티칼스, 인크. |
자가면역 질환의 치료 또는 예방을 위한 2,4-피리미딘디아민 화합물
|
|
WO2007098507A2
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
GB0605691D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
|
DK2089369T3
(da)
*
|
2006-10-19 |
2011-05-09 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
|
|
WO2009003136A1
(en)
*
|
2007-06-26 |
2008-12-31 |
Rigel Pharmaceuticals, Inc. |
Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
|
|
WO2009007839A1
(en)
*
|
2007-07-11 |
2009-01-15 |
Pfizer Inc. |
Pharmaceutical compositions and methods of treating dry eye disorders
|
|
CN101903357A
(zh)
*
|
2007-07-17 |
2010-12-01 |
里格尔药品股份有限公司 |
作为pkc抑制剂的环状胺取代的嘧啶二胺
|